23andMe Investor Day Presentation Deck
January 2022, 78 slides
  1. 23andMe
  2. Related Decks
  3. Investor Day Presentation Decks
day yee | 23andMe
disclaimer | 23andMe
agenda | 23andMe
introduction and founder | 23andMe
today news on and collaboration | 23andMe
highlights | 23andMe
our mission is to help people access understand and benefit from the human genome if | 23andMe
consumer powered flywheel | 23andMe
what coming | 23andMe
therapeutics program overview head of therapeutics | 23andMe
limited use of genetic data and lack of patient engagement constrain productivity drug development is inefficient | 23andMe
potential to more efficiently develop novel therapeutics by power need and speed years average ats tee | 23andMe
based target discovery playbook how it works or | 23andMe
our scale enables real time genetics health research a | 23andMe
we have generated a research and development pipeline covering multiple therapeutic areas | 23andMe
target discovery vision joe chief scientific officer therapeutics | 23andMe
my background | 23andMe
human genetics has the potential to double the probability of success in drug development wrong wrong outcomes and translational mitigate | 23andMe
focusing on translational research to link targets and outcomes | 23andMe
systematic scalable research platform yields novel drug targets | 23andMe
leveraging our i signature implicates pathway | 23andMe
me is an antibody against that can block mediated immune suppression mediated or | 23andMe
consumer powered flywheel | 23andMe
genetics based target discovery vice president human genetics | 23andMe
genome wide association studies | 23andMe
size and scale accelerate target discovery | 23andMe
be made without large scale sequencing | 23andMe
be made without large scale sequencing | 23andMe
imputation and enables discovery of vast majority of genes identified via sequencing | 23andMe
| 23andMe
understanding across multiple diseases | 23andMe
using to identify oncology targets | 23andMe
me a novel oncology antibody targeting low head of therapeutics development and senior clinical development fellow me | 23andMe
immune oncology i signature highlights genetically driven targets | 23andMe
was identified as a promising anti cancer drug target with proprietary oncology i genetic signature | 23andMe
is an immune | 23andMe
me me binds with high affinity to and inhibits signaling me | 23andMe
me shows enhancement of secretion than anti | 23andMe
phase study of me in patients with locally advanced or metastatic solid malignancies | 23andMe
is highly expressed in a subset of human tumors | 23andMe
why target the receptor instead of the | 23andMe
me targeting a genetically validated approach to anti cancer therapy | 23andMe
program first clinical stage oncology antibody targeting low head of therapeutics development | 23andMe
was identified as a promising anti cancer drug target with proprietary immune oncology i genetic signature | 23andMe
is a negative regulator of the axis inhibition of and may enhance activity | 23andMe
preclinical data supports combining with and inhibitors | 23andMe
phase study design | 23andMe
is part of the genetically validated axis and is progressing in clinical development | 23andMe
using genetics to inform clinical development low head of therapeutics development | 23andMe
what if we could use genetics to predict immune function and immune response to i agents | 23andMe
genetics based drug development | 23andMe
polygenic scores for hypothyroidism psoriasis predicted clinical efficacy to immune blockade | 23andMe
polygenic scores may predict safety and efficacy is incorporating clinical into our clinical trials use of polygenic scores could enable more efficient clinical development and improve the probability of success developing drugs in genetically defined patient populations may differentiate products based on better outcomes and improved benefit risk profiles providing the right drugs to the right patients | 23andMe
executive summary therapeutics | 23andMe
genetics based primary care vice president general manager consumer | 23andMe
impact of different factors on risk of premature death | 23andMe
opportunity to deliver genetics based primary at scale | 23andMe
what is genetics based wellness | 23andMe
personalized at scale acquiring health positions us to create a fully integrated offering across with accessible affordable driving strategic differentiation | 23andMe
the power of polygenic risk scores for personalized director product | 23andMe
consumer powered flywheel | 23andMe
our health service | 23andMe
genome wide association studies | 23andMe
prediction with polygenic scores feature selection modeling personalized risk estimates | 23andMe
using polygenic risk scores to meaningfully stratifying actual results | 23andMe
personalized risk report | 23andMe
releases releases | 23andMe
it not just about genetics it about prediction | 23andMe
using to predict real world outcomes | 23andMe
bending the curve with | 23andMe
opportunity for personalized at scale | 23andMe
delivering a genetics based primary care service chief clinical officer | 23andMe
health is fully integrated with a broad service offering | 23andMe
the future primary care complete | 23andMe
the future primary care complete | 23andMe
concluding remarks and founder | 23andMe
future of | 23andMe
a | 23andMe
See More
23andMe
Investor Day Presentation Decks
Diagnostics & Research Decks
Healthcare Decks
Explore Topics
Cancer
Primary care
Drug discovery
Health care
Recent decks by 23andMe
Investor Presentation
January 2024
Investor Presentation
April 2023
Investor Presentation
August 2022
Investor Presentation
February 2022
See all presentations by 23andMe (7 decks)
Related decks
Babylon
Investor Presentation
September 2021
Exscientia
Results
August 2023
Exscientia
Results
May 2022
Exscientia
IPO
September 2021
Recursion Pharmaceuticals
Investor Day
January 2023
Exscientia
Investor Presentation
March 2024
Exscientia
Results
November 2023
Exscientia
Investor Presentation
June 2022
Recent decks by 23andMe
See all presentations (7 decks)
Investor Presentation
January 2024
Investor Presentation
April 2023
Investor Presentation
August 2022
Investor Presentation
February 2022
Babylon
Investor Presentation
September 2021
Exscientia
Results
August 2023
Exscientia
Results
May 2022
Exscientia
IPO
September 2021
Recursion Pharmaceuticals
Investor Day
January 2023
Exscientia
Investor Presentation
March 2024
Exscientia
Results
November 2023
Exscientia
Investor Presentation
June 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io